RetroSearch Browse

Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/37022767/ below:

A modelled evaluation of the impact of COVID-19 on breast, bowel, and cervical cancer screening programmes in Australia

doi: 10.7554/eLife.82818. A modelled evaluation of the impact of COVID-19 on breast, bowel, and cervical cancer screening programmes in Australia Megan A Smith¹, Eleonora Feletto¹, Louiza S Velentzis^{1 2}, Kate Broun³, Sabine Deij^{1 2}, Paul Grogan¹, Michaela Hall¹, Emily He¹, D James St John^{3 4}, Jie-Bin Lew¹, Pietro Procopio^{1 2}, Kate T Simms¹, Joachim Worthington¹, G Bruce Mann^{5 6}, Karen Canfell¹

Affiliations

¹ Daffodil Centre, The University of Sydney, a Joint Venture with Cancer Council NSW, Sydney, Australia.
² Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia.
³ Prevention Division, Cancer Council Victoria, Melbourne, Australia.
⁴ Department of Medicine, The Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia.
⁵ Breast Service, The Royal Women's and Royal Melbourne Hospital, Melbourne, Australia.
⁶ Department of Surgery, University of Melbourne, Melbourne, Australia.

PMID: 37022767
PMCID: PMC10079286
DOI: 10.7554/eLife.82818

Item in Clipboard

A modelled evaluation of the impact of COVID-19 on breast, bowel, and cervical cancer screening programmes in Australia

Carolyn Nickson et al. Elife. 2023.

doi: 10.7554/eLife.82818. Authors Carolyn Nickson^{1 2}, Megan A Smith¹, Eleonora Feletto¹, Louiza S Velentzis^{1 2}, Kate Broun³, Sabine Deij^{1 2}, Paul Grogan¹, Michaela Hall¹, Emily He¹, D James St John^{3 4}, Jie-Bin Lew¹, Pietro Procopio^{1 2}, Kate T Simms¹, Joachim Worthington¹, G Bruce Mann^{5 6}, Karen Canfell¹ Affiliations

¹ Daffodil Centre, The University of Sydney, a Joint Venture with Cancer Council NSW, Sydney, Australia.
² Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia.
³ Prevention Division, Cancer Council Victoria, Melbourne, Australia.
⁴ Department of Medicine, The Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia.
⁵ Breast Service, The Royal Women's and Royal Melbourne Hospital, Melbourne, Australia.
⁶ Department of Surgery, University of Melbourne, Melbourne, Australia.

PMID: 37022767
PMCID: PMC10079286
DOI: 10.7554/eLife.82818

Item in Clipboard

Abstract

Australia introduced COVID-19 infection prevention and control measures in early 2020. To help prepare health services, the Australian Government Department of Health commissioned a modelled evaluation of the impact of disruptions to population breast, bowel, and cervical cancer screening programmes on cancer outcomes and cancer services. We used the Policy1 modelling platforms to predict outcomes for potential disruptions to cancer screening participation, covering periods of 3, 6, 9, and 12 mo. We estimated missed screens, clinical outcomes (cancer incidence, tumour staging), and various diagnostic service impacts. We found that a 12-mo screening disruption would reduce breast cancer diagnoses (9.3% population-level reduction over 2020-2021) and colorectal cancer (up to 12.1% reduction over 2020-21), and increase cervical cancer diagnoses (up to 3.6% over 2020-2022), with upstaging expected for these cancer types (2, 1.4, and 6.8% for breast, cervical, and colorectal cancers, respectively). Findings for 6-12-mo disruption scenarios illustrate that maintaining screening participation is critical to preventing an increase in the burden of cancer at a population level. We provide programme-specific insights into which outcomes are expected to change, when changes are likely to become apparent, and likely downstream impacts. This evaluation provided evidence to guide decision-making for screening programmes and emphasises the ongoing benefits of maintaining screening in the face of potential future disruptions.

Keywords: COVID-19; breast cancer; cancer screening; cervical cancer; colorectal cancer; epidemiology; global health.

PubMed Disclaimer

Conflict of interest statement

CN, EF, LV, KB, SD, PG, MH, EH, JL, PP, KS, JW, KC No competing interests declared, MS reports salary support via fellowship grants from the NHMRC of Australia and Cancer Institute NSW and contracts paid to her institution (the Daffodil Centre) with the Commonwealth Department of Health (Australia) and National Screening Unit (New Zealand), DS Receives salary support from National Health Medical Research Council Investigator grant (APP1194784), GM is a PI of an investigator-initiated trial of cervical screening, (Compass;ACTRN12613001207707 and NCT02328872) run by the Australian Centre for the Prevention of Cervical Cancer, which is a government-funded not-for-profit charity; the Australian Centre for the Prevention of Cervical Cancer has received equipment and a funding contribution from Roche Molecular Diagnostics. KC is also co-PI on a major investigator-initiated implementation program Elimination of Cervical Cancer in the Western Pacific (ECCWP) which will receive support from the Minderoo Foundation, the Frazer Family Foundation and equipment donations from Cepheid Inc Neither KC nor her institution on her behalf have received direct funding from industry for any project. KC receives salary support from a National Health and Medical Research Council (NHMRC) of Australia fellowship grant

Figures
Figure 1.. National change in number of…

Figure 1.. National change in number of screening tests by month, 2020 vs. 2019, for…
Figure 1.. National change in number of screening tests by month, 2020 vs. 2019, for the breast, bowel, and cervical screening programmes.

Derived from AIHW 2020 report – Cancer Screening and COVID19 in Australia. Australian Institute of Health and Welfare, 2020b. Note: cervical screening test volumes were anticipated to be lower in 2020 than in 2019 due to the extension from a 2-y to a 5-y screening interval (Smith et al., 2016).

Figure 2.. National proportional change in number…

Figure 2.. National proportional change in number of screening tests by month, 2020 vs. 2019,…
Figure 2.. National proportional change in number of screening tests by month, 2020 vs. 2019, for the breast, bowel, and cervix screening programmes.

Update of

doi: 10.1101/2022.09.11.22279831